Nicole C Foster1, Roy W Beck1, Kellee M Miller1, Mark A Clements2, Michael R Rickels3, Linda A DiMeglio4, David M Maahs5, William V Tamborlane6, Richard Bergenstal7, Elizabeth Smith1, Beth A Olson7, Satish K Garg8. 1. 1 Jaeb Center for Health Research, Tampa, Florida. 2. 2 Endocrine/Diabetes Department, Children's Mercy Hospital, Kansas City, Missouri. 3. 3 Rodebaugh Diabetes Center, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania. 4. 4 Department of Pediatrics, Indiana University School of Medicine, Indianapolis Indiana. 5. 5 Department of Pediatrics-Endocrinology, Stanford University, Stanford, California. 6. 6 Pediatric Endocrinology and Diabetes, Yale University School of Medicine, New Haven, Connecticut. 7. 7 International Diabetes Center Park Nicollet, Minneapolis, Minnesota. 8. 8 Barbara Davis Center for Childhood Diabetes, University of Colorado Denver, Aurora, Colorado.
Abstract
OBJECTIVE: To provide a snapshot of the profile of adults and youth with type 1 diabetes (T1D) in the United States and assessment of longitudinal changes in T1D management and clinical outcomes in the T1D Exchange registry. RESEARCH DESIGN AND METHODS: Data on diabetes management and outcomes from 22,697 registry participants (age 1-93 years) were collected between 2016 and 2018 and compared with data collected in 2010-2012 for 25,529 registry participants. RESULTS: Mean HbA1c in 2016-2018 increased from 65 mmol/mol at the age of 5 years to 78 mmol/mol between ages 15 and 18, with a decrease to 64 mmol/mol by age 28 and 58-63 mmol/mol beyond age 30. The American Diabetes Association (ADA) HbA1c goal of <58 mmol/mol for youth was achieved by only 17% and the goal of <53 mmol/mol for adults by only 21%. Mean HbA1c levels changed little between 2010-2012 and 2016-2018, except in adolescents who had a higher mean HbA1c in 2016-2018. Insulin pump use increased from 57% in 2010-2012 to 63% in 2016-2018. Continuous glucose monitoring (CGM) increased from 7% in 2010-2012 to 30% in 2016-2018, rising >10-fold in children <12 years old. HbA1c levels were lower in CGM users than nonusers. Severe hypoglycemia was most frequent in participants ≥50 years old and diabetic ketoacidosis was most common in adolescents and young adults. Racial differences were evident in use of pumps and CGM and HbA1c levels. CONCLUSIONS: Data from the T1D Exchange registry demonstrate that only a minority of adults and youth with T1D in the United States achieve ADA goals for HbA1c.
OBJECTIVE: To provide a snapshot of the profile of adults and youth with type 1 diabetes (T1D) in the United States and assessment of longitudinal changes in T1D management and clinical outcomes in the T1D Exchange registry. RESEARCH DESIGN AND METHODS: Data on diabetes management and outcomes from 22,697 registry participants (age 1-93 years) were collected between 2016 and 2018 and compared with data collected in 2010-2012 for 25,529 registry participants. RESULTS: Mean HbA1c in 2016-2018 increased from 65 mmol/mol at the age of 5 years to 78 mmol/mol between ages 15 and 18, with a decrease to 64 mmol/mol by age 28 and 58-63 mmol/mol beyond age 30. The American Diabetes Association (ADA) HbA1c goal of <58 mmol/mol for youth was achieved by only 17% and the goal of <53 mmol/mol for adults by only 21%. Mean HbA1c levels changed little between 2010-2012 and 2016-2018, except in adolescents who had a higher mean HbA1c in 2016-2018. Insulin pump use increased from 57% in 2010-2012 to 63% in 2016-2018. Continuous glucose monitoring (CGM) increased from 7% in 2010-2012 to 30% in 2016-2018, rising >10-fold in children <12 years old. HbA1c levels were lower in CGM users than nonusers. Severe hypoglycemia was most frequent in participants ≥50 years old and diabetic ketoacidosis was most common in adolescents and young adults. Racial differences were evident in use of pumps and CGM and HbA1c levels. CONCLUSIONS: Data from the T1D Exchange registry demonstrate that only a minority of adults and youth with T1D in the United States achieve ADA goals for HbA1c.
Authors: Eveline R Goethals; Sarah S Jaser; Chris Verhaak; Sofie Prikken; Kristina Casteels; Koen Luyckx; Alan M Delamater Journal: Diabetes Res Clin Pract Date: 2020-04-20 Impact factor: 5.602
Authors: Rayhan A Lal; Nicolas Cuttriss; Michael J Haller; Katarina Yabut; Claudia Anez-Zabala; Korey K Hood; Eleni Sheehan; Marina Basina; Angelina Bernier; Linda G Baer; Stephanie L Filipp; C Jason Wang; Marissa A Town; Matthew J Gurka; David M Maahs; Ashby F Walker Journal: Clin Diabetes Date: 2020-04
Authors: Dayna E McGill; Lori M Laffel; Lisa K Volkening; Deborah A Butler; Wendy L Levy; Rachel M Wasserman; Barbara J Anderson Journal: Diabetes Technol Ther Date: 2020-05 Impact factor: 6.118
Authors: Christine A March; Michelle Nanni; Traci M Kazmerski; Linda M Siminerio; Elizabeth Miller; Ingrid M Libman Journal: Pediatr Diabetes Date: 2020-04-22 Impact factor: 4.866
Authors: Boris P Kovatchev; Laura Kollar; Stacey M Anderson; Charlotte Barnett; Marc D Breton; Kelly Carr; Rachel Gildersleeve; Mary C Oliveri; Christian A Wakeman; Sue A Brown Journal: Lancet Digit Health Date: 2020-01-03